BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 08/11/2016
Entire Document
 


BioLineRx Ltd.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)

   
Three months ended June 30,
   
Six months ended June 30,
 
   
2015
   
2016
   
2015
   
2016
 
   
in USD thousands
   
in USD thousands
 
RESEARCH AND DEVELOPMENT EXPENSES, NET
   
(2,891
)
   
(2,740
)
   
(6,102
)
   
(5,279
)
SALES AND MARKETING EXPENSES
   
(299
)
   
(272
)
   
(559
)
   
(520
)
GENERAL AND ADMINISTRATIVE EXPENSES
   
(976
)
   
(854
)
   
(1,832
)
   
(1,843
)
OPERATING LOSS
   
(4,166
)
   
(3,866
)
   
(8,493
)
   
(7,642
)
NON-OPERATING INCOME (EXPENSES), NET
   
(847
)
   
48
     
(887
)
   
196
 
FINANCIAL INCOME
   
205
     
88
     
278
     
232
 
FINANCIAL EXPENSES
   
(2
)
   
(5
)
   
(19
)
   
(9
)
                                 
NET LOSS AND COMPREHENSIVE LOSS
   
(4,810
)
   
(3,735
)
   
(9,121
)
   
(7,223
)
                                 
   
in USD
   
in USD
 
LOSS PER ORDINARY SHARE - BASIC AND DILUTED
   
(0.09
)
   
(0.07
)
   
(0.19
)
   
(0.13
)
                                 
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE
   
53,562,019
     
56,423,601
     
48,095,879
     
55,651,371
 

7